[go: up one dir, main page]

PE20080671A1 - DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA - Google Patents

DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA

Info

Publication number
PE20080671A1
PE20080671A1 PE2007001266A PE2007001266A PE20080671A1 PE 20080671 A1 PE20080671 A1 PE 20080671A1 PE 2007001266 A PE2007001266 A PE 2007001266A PE 2007001266 A PE2007001266 A PE 2007001266A PE 20080671 A1 PE20080671 A1 PE 20080671A1
Authority
PE
Peru
Prior art keywords
phenyl
imidazo
cycloalkyl
alkyl
pyridines
Prior art date
Application number
PE2007001266A
Other languages
English (en)
Inventor
Antonio Almario-Garcia
Patrick Lardenois
Anne Olivier
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20080671A1 publication Critical patent/PE20080671A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS DE FORMULA (I) DONDE R1 ES FENILO O NAFTILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C6), CICLOALQUILO(C3-C7), ALCOXI(C1-C6), ENTRE OTROS; R2 Y R3 SON CADA UNO H, ALQUILO(C1-C6), CICLOALQUILO(C3-C7), CICLOALQUIL(C3-C7)ALQUILENO(C1-C3) OPCIONALMENTE SUSTITUIDO CON Rf, ENTRE OTROS, DONDE Rf ES HALOGENO, ALCOXI(C1-C6), CN, HIDROXILO, ENTRE OTROS; R4 ES H, ALQUILO(C1-C6), ARILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C6), CN, NITRO, ENTRE OTROS SUSTITUYENTES, CICLOALQUILO(C3-C7), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: [4-(2-FENILIMIDAZO[1,2-a]PIRIDIN-6-IL)FENIL]METANOL, {4-[2-(4-PIRROLIDIN-1-ILFENIL)-IMIDAZO[1,2-a]PIRIDIN-6-IL]FENIL}METANOL, [4-(2-BIFENIL-4-ILIMIDAZO[1,2-a]PIRIDIN-6-IL)FENIL]METANOL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES NUCLEARES NURR1 SIENDO UTILES EN EL TRATAMIENTO DE EPILEPSIA, OSTEOPOROSIS, ENFERMEDAD DE PARKINSON, ENFERMEDAD DE ALZHEIMER
PE2007001266A 2006-09-22 2007-09-20 DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA PE20080671A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0608350A FR2906250B1 (fr) 2006-09-22 2006-09-22 Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
PE20080671A1 true PE20080671A1 (es) 2008-07-14

Family

ID=37841968

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001266A PE20080671A1 (es) 2006-09-22 2007-09-20 DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA

Country Status (43)

Country Link
US (1) US7915284B2 (es)
EP (1) EP2069342B1 (es)
JP (1) JP5336378B2 (es)
KR (1) KR101470039B1 (es)
CN (1) CN101516881B (es)
AR (1) AR062897A1 (es)
AT (1) ATE467633T1 (es)
AU (1) AU2007298856B2 (es)
BR (1) BRPI0718517A2 (es)
CA (1) CA2662848C (es)
CL (1) CL2007002733A1 (es)
CO (1) CO6160308A2 (es)
CR (1) CR10643A (es)
CY (1) CY1110232T1 (es)
DE (1) DE602007006525D1 (es)
DK (1) DK2069342T3 (es)
EA (1) EA017442B1 (es)
ES (1) ES2345016T3 (es)
FR (1) FR2906250B1 (es)
GT (1) GT200900049A (es)
HN (1) HN2009000502A (es)
HR (1) HRP20100408T1 (es)
IL (1) IL197352A (es)
JO (1) JO2643B1 (es)
MA (1) MA30792B1 (es)
ME (1) ME00615B (es)
MX (1) MX2009002802A (es)
MY (1) MY145603A (es)
NI (1) NI200900037A (es)
NO (1) NO20091562L (es)
NZ (1) NZ575337A (es)
PE (1) PE20080671A1 (es)
PL (1) PL2069342T3 (es)
PT (1) PT2069342E (es)
RS (1) RS51412B (es)
SI (1) SI2069342T1 (es)
SV (1) SV2009003193A (es)
TN (1) TN2009000081A1 (es)
TW (1) TWI381837B (es)
UA (1) UA95976C2 (es)
UY (1) UY30603A1 (es)
WO (1) WO2008034974A1 (es)
ZA (1) ZA200901551B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
FR2928924B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2928921B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2928922B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2933609B1 (fr) * 2008-07-10 2010-08-27 Fournier Lab Sa Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
FR2950345B1 (fr) * 2009-09-18 2011-09-23 Sanofi Aventis Derives acetyleniques de 5-phenyl-pyrazolopyridine, leur preparation et leur application en therapeutique
FR2950344B1 (fr) * 2009-09-18 2011-11-25 Sanofi Aventis Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.
FR2953520B1 (fr) * 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
EP2925756B1 (en) * 2012-11-29 2017-02-01 F. Hoffmann-La Roche AG Imidazopyridine derivatives
EP2951170B1 (en) * 2013-02-04 2018-10-24 Janssen Pharmaceutica NV Flap modulators
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Flap調節劑
RU2734760C2 (ru) * 2013-08-02 2020-10-23 Энститю Пастер Корея Противоинфекционные соединения
JP6806342B2 (ja) 2015-04-10 2021-01-06 ベイジーン リミテッド インドールアミンとしての新規5又は8−置換イミダゾ[1,5−a]ピリジン類、及び/又はトリプトファン2,3−ジオキシゲナーゼ
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
LT3377488T (lt) 2015-11-19 2023-01-10 Incyte Corporation Heterocikliniai junginiai, kaip imunomoduliatoriai
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US10882856B2 (en) 2016-09-24 2021-01-05 Beigene, Ltd. 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
JP7303108B2 (ja) 2016-12-22 2023-07-04 インサイト・コーポレイション 免疫調節剤としての二環式複素芳香環化合物
CN116115764A (zh) 2016-12-22 2023-05-16 因赛特公司 四氢咪唑并[4,5-c]吡啶衍生物作为pd-l1内在化诱导剂
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
US11472788B2 (en) 2017-11-25 2022-10-18 Beigene, Ltd. Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases
ES3030010T3 (en) 2018-03-30 2025-06-26 Incyte Corp Heterocyclic compounds as immunomodulators
BR112020022936A2 (pt) 2018-05-11 2021-02-02 Incyte Corporation derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrimido[3,2–D]pyrimidine compounds as immunomodulators
JP2023500395A (ja) 2019-11-11 2023-01-05 インサイト・コーポレイション Pd-1/pd-l1阻害剤の塩及び結晶形態
JP7605504B2 (ja) * 2019-11-13 2024-12-24 アプリノイア セラピューティクス リミテッド タウタンパク質凝集物を分解する化合物及びその使用
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備pd-1/pd-l1抑制劑以及其鹽及結晶形式之方法
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4041624B2 (ja) * 1999-07-21 2008-01-30 三井化学株式会社 有機電界発光素子
WO2001074813A2 (en) * 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS
GB0119911D0 (en) * 2001-08-15 2001-10-10 Novartis Ag Organic Compounds
JP4845379B2 (ja) * 2002-09-19 2011-12-28 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
AU2005220882A1 (en) * 2004-03-08 2005-09-22 Georgia State University Research Foundation, Inc Novel dicationic imidazo(1,2-a)pyridines and 5,6,7,8-tetrahydro-imidazo(1,2a)pyridines as antiprotozoal agents

Also Published As

Publication number Publication date
US20090253735A1 (en) 2009-10-08
JO2643B1 (en) 2012-06-17
CR10643A (es) 2009-04-29
TWI381837B (zh) 2013-01-11
JP2010504309A (ja) 2010-02-12
NO20091562L (no) 2009-04-20
MX2009002802A (es) 2009-04-01
UY30603A1 (es) 2008-05-02
IL197352A0 (en) 2009-12-24
HN2009000502A (es) 2011-07-11
HRP20100408T1 (hr) 2010-09-30
MEP10709A (en) 2011-12-20
UA95976C2 (en) 2011-09-26
FR2906250B1 (fr) 2008-10-31
AU2007298856B2 (en) 2012-08-09
US7915284B2 (en) 2011-03-29
TW200833329A (en) 2008-08-16
BRPI0718517A2 (pt) 2013-11-19
CA2662848A1 (fr) 2008-03-27
CN101516881B (zh) 2012-07-18
CO6160308A2 (es) 2010-05-20
PL2069342T3 (pl) 2010-10-29
NZ575337A (en) 2011-12-22
EA017442B1 (ru) 2012-12-28
SV2009003193A (es) 2010-02-01
AR062897A1 (es) 2008-12-10
EA200970311A1 (ru) 2009-08-28
PT2069342E (pt) 2010-07-19
HK1135388A1 (en) 2010-06-04
EP2069342A1 (fr) 2009-06-17
CA2662848C (fr) 2014-12-23
CL2007002733A1 (es) 2008-04-11
ES2345016T3 (es) 2010-09-13
MY145603A (en) 2012-03-15
KR20090054449A (ko) 2009-05-29
FR2906250A1 (fr) 2008-03-28
ATE467633T1 (de) 2010-05-15
ME00615B (me) 2011-12-20
SI2069342T1 (sl) 2010-09-30
GT200900049A (es) 2010-03-04
EP2069342B1 (fr) 2010-05-12
NI200900037A (es) 2014-02-20
CY1110232T1 (el) 2015-01-14
DE602007006525D1 (de) 2010-06-24
JP5336378B2 (ja) 2013-11-06
WO2008034974A1 (fr) 2008-03-27
RS51412B (sr) 2011-02-28
CN101516881A (zh) 2009-08-26
KR101470039B1 (ko) 2014-12-05
IL197352A (en) 2014-11-30
DK2069342T3 (da) 2010-08-23
TN2009000081A1 (en) 2010-08-19
ZA200901551B (en) 2010-06-30
AU2007298856A1 (en) 2008-03-27
MA30792B1 (fr) 2009-10-01

Similar Documents

Publication Publication Date Title
PE20080671A1 (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20091819A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA
PE20091694A1 (es) DERIVADOS POLISUSTITUIDOS DE 6-HETEROARIL-IMIDAZO[1,2-a] PIRIDINAS COMO MODULADORES DE LOS RECEPTORES NOT Y SU PREPARACION
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
PE20080772A1 (es) Nuevos derivados de bipiridina sustituidos y su uso
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20091623A1 (es) DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20090679A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20090960A1 (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas
PE20080552A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
PE20120113A1 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
PE20090492A1 (es) Compuestos heterociclos como inhibidores de cinasa de fosfatidil-inositol-3
PE20090904A1 (es) ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
PE20060949A1 (es) Derivados fusionados de pirazol como agonistas del receptor de niacina
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed